Hyaluronan-enriched Medium and Euploid Blastocyst Transfers

The study period will be determined by the completion of the predetermined sample size, with two interim analyses planned when 35% (n=274) and 70% (n=548) of the target sample size is achieved to calculate conditional power. If conditional power is estimated to be lower than 15% at first interim analysis or lower than 30% in the second interim analysis, the trial will be stopped due to futility. The study will be performed in Abu Dhabi-Fertility clinic. During the period of this prospective study, euploid blastocysts of enough quality that have been biopsied only on Day-5 for PGT-A, will be warmed for single blastocyst transfer. The patient´s endometrial preparation protocol for FET will be restricted to HRT only. The study will be double-blinded (blinded to patient and doctor performing transfer).

Inclusion criteria

• All frozen embryo transfer (FET) cycles with euploid blastocysts biopsied and vitrified on Day 5 after PGT-A.
• Rank of randomization based on embryo quality.
• Only hormonal replacement theraphy (HRT) cycle regimen.
• Women aged 18 years to 46 years.
• Having at least 1 chromosomally normal vitrified blastocyst(s) on Day 5 available for transfer.
• All sperm samples.
• BMI between 18 and 35.

Exclusion criteria

• FET cycles with preimplantation genetic testing for monogenic disorders (PGT-M) and for structural rearrangements (PGT-SR).
• FET cycles with mosaic / aneuploid blastocysts.
• FET cycles with unknown outcome.
• FET cycles with Day 6 or Day 7 biopsied blastocysts.
• FET with patients' endometrium preparation with treatments other than HRT.
• FET where PGT-A was performed for gender selection.